AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease
Birmingham, Alabama, and London, England, 1 September 2022 – AeroNeph Therapeutics (“AeroNeph”; www.aeroneph.com), a pioneer in discovery of renal disease assets, has announced its corporate launch in the USA. AeroNeph has acquired its drug candidates from preclinical CRO Discovery Biomed who have used a revolutionary human disease approach to drug discovery; Discovery Biomed was acquired by Eurofins Discovery in July 2022, a leading global CRO. AeroNeph’s focus is on Polycys